glp 1 drugs and alcohol GLP-1 receptor agonists may protect the liver during consumption GLP-1 Receptor Agonists and Research

Research shows that taking both supplements together might work better than using them separately

Findings: RCTSTEP UP Trial - Semaglutide 7.2 mg once weekly vs Semaglutide 2.4 mg once weekly in Obese Adults, Lancet Diabetes Endocrinol (2025) [PubMed abstract] Design: Randomized, double-blind, placebo-controlled and active-controlled trial (N=1407 | length = 72 weeks) in adults with BMI 30 without diabetes Treatment: Semaglutide 7.2 mg once weekly vs Semaglutide 2.4 mg once weekly vs Placebo Primary outcome: Percentage change in body weight and the proportion of participants with a body weight reduction of 5% or greater Results: Primary outcome (% decrease in body weight): Semaglutide 7.2 mg - 18.7%, Semaglutide 2.4 mg - 15.6%, Placebo - 3.9% (p 5kg within 90 days) History of chronic pancreatitis Acute pancreatitis within 180 days Baseline characteristics Average age 48 years Female sex - 79% Average weight - 233 lbs (106 kg) Average BMI - 37.6 Randomized treatment groups Group 1 (205 patients): Oral Semaglutide with a target dose of 25 mg once daily Group 2 (102 patients): Placebo Semaglutide was started at 3 mg daily and increased every 4 weeks to 7 mg, 14 mg, and 25 mg All patients also received diet (500 kcal deficit) and exercise (150 min/week) counseling Coprimary endpoints were the percentage change in body weight from baseline to week 64 and achievement of a reduction in body weight of 5% or more from baseline to week 64 Primary outcome: Results Oral semaglutide at a dose of 25 mg once daily resulted in a greater mean reduction in body weight than placebo in participants with overweight or obesity

Frommer L, Kahaly GJ

If so, your bodys filtration and detoxification systems (particularly the liver and kidneys) have been working overtime to process it all

Treatment of prostate cancer based on LH-RH agonists averted the psychological impact of castration as well as the cardiovascular, hepatic, and mammary gland stimulation-related side effects of estrogen